Drugs / CT001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04807335 | Mar → Jun 2021 | — | Cessatech A/S | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05508594 | Sep 2022 → Oct 2023 | — | Cessatech A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04807335 ↗ |
| Route | Intranasal | “intranasal dosage of CT001” NCT04807335 ↗ |